

Daily evidence digest

20 October 2021

The daily evidence digest collates recently released reports and evidence – provision of these links does not imply endorsement nor recommendation.

COVID-19 vaccines against Delta, a post-exposure nasal spray, methods for short term forecasts of COVID-19 admissions

Peer reviewed journals featured:

- A systematic review on the effectiveness of COVID-19 vaccines against the Delta variant [here](#)
- A randomised controlled study of nasal spray containing Iota-Carrageenan in postexposure prophylaxis of COVID-19 in healthcare workers [here](#)
- Observational studies on:
 - Risk of SARS-CoV-2 transmission from on-field player contacts in football (soccer) [here](#)
 - Asymptomatic COVID-19 outpatients and SARS-CoV-2 shedding [here](#)
- Commentary on vaccine-induced immune thrombotic thrombocytopenia [here](#)

Letters and correspondence discussed:

- The readability of official public health information on COVID-19 [here](#)
- Asymptomatic COVID-19 vaccine breakthrough infections in healthcare workers identified through routine universal surveillance testing [here](#)
- A case of multisystem inflammatory syndrome in adults (MIS-A) during the Delta outbreak in NSW [here](#)

Pre-peer review articles featured:

- Comparative assessment of methods for short-term forecasts of COVID-19 admissions [here](#)
- Reduced seroconversion in children compared to adults with mild COVID-19 [here](#)
- Viral loads in patients with Delta variant infection [here](#)
- Effectiveness of Vaxzevria (AstraZeneca) versus Comirnaty (Pfizer) vaccines in health and social care workers in England [here](#)

Guidance and reports

- The World Health Organization published papers on building health system resilience during COVID-19 and beyond [here](#) and [here](#)
- The Canadian National Collaborating Centre for Methods and Tools updated its review on effectiveness, immunogenicity, and safety of COVID-19 vaccines in infected people [here](#)

News and blogs

- Valneva's vaccine produces stronger immune response than Vaxzevria's (AstraZeneca) [here](#)
- Prevalence rises among school children in England [here](#)
- International health and care worker deaths during COVID-19 [here](#)

[Click here](#) to subscribe to the daily evidence digest.

Living Evidence Tables

Living Evidence tables are up-to-date summaries of emerging evidence. Tables are available on [COVID-19 transmission](#), SARS-CoV-2 [vaccines](#), and [variants](#) of concern, [post-acute sequelae of COVID-19 \(PASC\)](#), [surgery and COVID-19](#), [rapid testing](#) and [risk mitigation strategies](#).